Key result
Higher adipokine score linked to ~3% higher odds of metabolic syndrome per point.
Answers are grounded in this paper and cite their sources.
Adipose tissue acts as a dynamic endocrine organ producing adipokines, a family of peptides with heterogeneous metabolic activities.1 Several adipokines (e.g. tumour necrosis factor-α (TNF-α), interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), adipsin, chemerin, nerve growth factor (NGF), soluble serum amyloid A1 (SAA1), resistin, migration inhibitory factor (MIF), plasminogen activator inhibitor-1 (PAI-1) and hepatic growth factor (HGF)) have been found to exert adverse metabolic and vascular effects through their proinflammatory and prothrombotic effects.1 Of note, increased levels of resistin and related adipokines have been shown to independently increase the risk of vascular events by 44% in healthy individuals.2 Conversely, leptin, adiponectin, apelin and visfatin have been distinguished by their anti-inflammatory and insulin-sensitizing properties.1,3,4 Higher adiponectin levels, acting by down-regulation of proinflammatory mediators and by improving endothelial function,5,6 have been associated with improvement of some metabolic syndrome characteristics7 and with less severe cardiac ischaemia and reperfusion injury following an acute myocardial infarction.8 There is evidence suggesting that adverse metabolic and cardiovascular effects result from complex changes in the composition and metabolism of adipose tissue (i.e. adipose tissue dysfunction (ATD)). ATD is characterized by a significant imbalance in adipokine profile, with a predominance of proinflammatory and prothrombotic adipokines.9 This is frequently seen in obesity, but it can also occur in normal-weight individuals and is strongly related to visceral adiposity,10 a hallmark of the metabolic syndrome.11 However, the characteristics of ATD and its association with the metabolic syndrome are not fully elucidated. Therefore, clarifying these issues may be relevant for the guidance of pharmacological and lifestyle interventions. In the current issue of the European Journal of Preventive Cardiology, Schrover and colleagues explore the relationship between 11 adipokines considered to reflect ATD, regional body fat distribution and the likelihood of the metabolic syndrome in a cross-sectional study including 1215 patients with various vascular diseases. The association between adipokines and the metabolic syndrome was assessed for individual adipokines and for an ‘adipokine profile’, which was constructed by summation of equally weighted quartiles of all analysed adipokine levels. Adiposity parameters included body mass index (BMI), waist circumference, subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT), as assessed by echo sonography.12 The results of the present study showed that higher BMI, waist circumference and VAT correlated with increased levels of NGF, HGF, MIF, leptin and adipsin, and the strongest positive relation was found between BMI, adipsin and leptin. Conversely, an inverse relation was seen between adiposity parameters and chemerin, PAI-1, resistin, SAA1 and adiponectin. The strongest negative relation was found between BMI and SAA1 and between VAT and adiponectin. Importantly, there was no significant relationship between SAT and adipokine levels. Following adjustment for potential confounders, HGF and leptin were found to increase the likelihood of the metabolic syndrome by 21% and 26%, respectively. On the other hand, adiponectin and resistin appeared to have a protective role, as they both decreased the likelihood of the metabolic syndrome, by 27% and 15%, respectively. Finally, in the multivariable analysis, each point higher sum of adipokines, expressed as the adipokine profile, increased the likelihood of the metabolic syndrome (odds ratio (OR) 1.03, 95% confidence interval (CI) 1.00–1.06), while further adjustment for VAT slightly attenuated this relationship (OR 1.02, 95% CI 0.99–1.05). There are several limitations in the interpretation of the current study. It was performed in patients with overt vascular disease, and the characteristics of the analysed adipokines are more likely to reflect patients with advanced atherosclerosis compared with the general population. Furthermore, the adipokine profile, which was constructed by combining multiple adipokine levels, should be viewed as hypothesis generating rather than an accurate measure of their mutual influence on patients’ metabolism. Although the use of a large number of adipokines in the present study is commendable from the perspective of advancing research, it would be challenging to use it in clinical practice. Finally, it has to be taken into account that variations in lifestyle habits, food intake and concomitant medications might have influenced adipokine levels and possibly confounded the association with the metabolic syndrome.13–15 Obesity is a growing public health problem affecting over 500 million adults worldwide16 and is related to an excess cardiovascular risk.17 This relationship is not simply a consequence of an increased BMI,18 because 10–30% of obese individuals are ‘metabolically healthy’ (i.e. without overt metabolic abnormalities), but they still exhibit increased cardiovascular risk.19,20 Data suggest that accumulation of VAT, rather than SAT, is responsible for ATD, with subsequent development of insulin resistance, type 2 diabetes, dyslipidaemia, chronic inflammation and endothelial dysfunction.21–23 In the Multi-Ethnic Study of Atherosclerosis, a single measure of VAT, as well as VAT enlargement over time, has been found to predict the development of the metabolic syndrome, independent of BMI.24 Visceral adipose index, a composite model based on waist circumference, BMI, triglycerides and high-density lipoprotein levels, has been strongly related to a disturbed adipokine profile.25 Importantly, there is a growing body of evidence linking VAT to adverse cardiovascular outcomes. In a prospective Health, Aging and Body Composition Study, VAT has been identified as an independent predictor of incident myocardial infarction.26 Likewise, in a long-term follow-up of individuals from the Framingham Heart Study, increased VAT volume has been an independent predictor of incident cardiovascular disease and cancer.27 In the study by Schrover and colleges, there has been no correlation between adipokine levels and SAT, which is in line with earlier findings that SAT is not the likely source of ATD. Importantly, this study expands the knowledge on ATD by demonstrating that several adipokines and their composite measure (i.e. the adipokine profile) have been associated with the metabolic syndrome and that this association persisted even after adjusting for VAT. This observation indicates that adipokine dysregulation is more relevant for metabolic abnormalities than adiposity per se, including the increased volume of VAT. This may explain the excess in cardiometabolic risk among the normal-weight individuals, in whom ATD may also be present.10 Unexpectedly, several adipokines with well-known proinflammatory and prothrombotic properties (i.e. chemerin, PAI-1, resistin and SAA1) have been inversely related to adiposity parameters, while resistin appeared to decrease the odds for the metabolic syndrome in the present study. As suggested by the authors, these paradoxical observations may be explained by the ‘index event bias’ that occurred as a consequence of selecting patients with manifest vascular disease. In these patients, congruence of multiple risk factors, including adipokines, which are related to both vascular disease and the metabolic syndrome, may have resulted in attenuation or paradoxical inversion of their association with the metabolic syndrome once vascular disease has occurred.28,29 Still, it has to be acknowledged that in patients with overt vascular disease, adipokine profile may substantially differ from the general population, and the observed contradictory relations may actually reflect unrecognized disease processes. Along the same lines, it is possible that concomitant therapy such as aspirin, antihypertensive and lipid-lowering agents, which the majority of patients were using, could account for some of the unexpected results. Aspirin has been shown to reduce plasma levels of PAI-1,30 while statins and antihypertensive drugs could decrease the levels of SAA1 and chemerin.31 Although still inconclusive, statins and some other drugs may modulate resistin plasma levels or its downstream metabolic actions, which could explain a paradoxical protective effect of resistin in the present study.32,33 Likewise, physical activity combined with lipid-lowering drugs has been shown to substantially reduce SAA1 levels.31 On the other hand, fibrates, statins and angiotensin converting enzyme inhibitors have been recognized to increase adiponectin concentrations34,35 and a similar effect has been described with the Mediterranean diet and healthy eating habits.36,37 Moreover, moderate alcohol intake has been shown to have a favorable effect on the serum lipid profile,38 and to increase adiponectin levels irrespective of obesity.39 Hence, the effects of lifestyle modification on ATD require further investigation. There is also an issue of gender-related dimorphism in adipose tissue distribution, which is characterized by a more pronounced deposition of SAT than VAT in women and more abundant VAT accumulation in men that could produce differences in adipokine profile.40 According to recent evidence, upper body fat accumulation in both sexes, in addition to abdominal adiposity, may further increase the cardiometabolic risk.41 Several studies have shown that women have higher levels of metabolically protective adipokines such as leptin and adiponectin.42,43 Also, a higher expression of chemerin mRNA has been observed in women than in men, but there has been a negative correlation with chemerin plasma levels and with markers of insulin-resistance, which suggests a negative feedback regulation and a possibility of a sex-specific pattern of chemerin biologic actions.44 Potential sex-related differences in adipokine profile have not been addressed in depth in the present study, but an analysis restricted to male patients (who accounted for 80% of the study population) has shown results consistent with the overall study population with respect to the relation between adipokines and the metabolic syndrome. From the clinical perspective, adipokines could be used as biomarkers to estimate changes in adipose tissue volume and distribution, and to gain insight into pathological processes attributed to ATD.45 According to the results of a randomized study that has assessed effects of dietary intervention on weight loss and adipokine profile, leptin levels have been tightly correlated with body weight changes, with a negative trend observed with weight loss and a switch in the opposite direction with weight regain.46 Conversely, adiponectin levels demonstrate continued long-term improvements despite weight regain, which may be a marker of a continuous beneficial response to a healthy eating pattern.46 Proinflammatory adipokines, such as TNFα, IL-6 and MCP-1, have been associated with macrophage infiltration into the adipose tissue, and the development of insulin resistance and hepatic steatosis.4 Upregulation of resistin levels during weight gain has been related to insulin resistance and type 2 diabetes.47 Among the healthy individuals from the Framingham Offspring Study, the prevalence of insulin resistance has been positively related to resistin and TNFα levels and negatively related to adiponectin levels.48 This relation has been observed in individuals with and without the metabolic syndrome, independent of BMI. In addition, a large community-based cohort study with a long-term prospective follow-up has shown that increasing adiponectin levels are associated with a lower risk of type 2 diabetes and subsequent adverse cardiovascular events.49 Furthermore, adipokines have been successfully used to assess the effects of therapeutic interventions in patients at high cardiometabolic risk. As shown in patients with type 2 diabetes and coronary artery disease, insulin sensitization with metformin and/or thiazolidinediones has produced more favourable changes in the adipokine profile and inflammatory mediators over a one-year follow-up period compared with insulin or sulphonylurea treatment.50 In the study by Schrover et al., the association between the investigated adipokines and the metabolic syndrome in individuals with vascular disease may provide an important insight into a residual cardiometabolic risk.51 This risk could be prospectively monitored and targeted with pharmacological, dietary and lifestyle interventions, which will potentially improve outcomes. In addition, the authors relate specific adipokines to either higher or lower odds for the metabolic syndrome, irrespective of other adiposity parameters, which could be relevant for the clinical follow-up. The authors also introduce a concept of the composite adipokine profile as an intriguing novel approach to summarize the biologic effects of multiple adipokines, which deserves further investigation. Further research is also needed to elucidate the conflicting results regarding the roles of SAA1, PAI-1, chemerin and resistin, and to identify adipokines with the strongest association with the metabolic syndrome and adverse cardiovascular outcomes among high-risk patients. As more data about adipokine mechanisms are becoming available, there is hope for their translation into clinical use. The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. The author(s) received no financial support for the research, authorship, and/or publication of this article.
No takes yet. Share an insight, caveat, or question.
Veljić et al. (2018) conducted an editorial in Overt vascular disease and metabolic syndrome (n=1,215). Adipokine profile (composite sum of equally weighted quartiles of 11 adipokines) vs. Lower adipokine profile score (per point increase) was evaluated on Likelihood of the metabolic syndrome (OR 1.03, 95% CI 1.00-1.06). Each point higher sum of 11 adipokines (adipokine profile) was associated with an increased likelihood of the metabolic syndrome in patients with vascular disease.
Synapse has enriched 10 related papers. Consider them for comparative context: